{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-26-000028","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2026-06-18T20:55:31+00:00","discovered_at":"2026-06-18T20:57:00.203899+00:00","generated_at":"2026-06-18T20:57:14.935854+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Supernus shareholders approve all proposals, including equity plan share increase","bullets":["Elected Class I directors Frederick M. Hudson (45.1M for) and Charles W. Newhall, III (41.7M for).","Say-on-pay approved with 45.6M votes for, 1.7M against, 7.7K abstain.","Ratified KPMG as auditor for FY2026 (49.9M for, 417K against).","Amendment to 2021 Equity Incentive Plan to increase shares available passed (41.9M for, 5.3M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-26-000028","json":"https://secwatch.observer/filing/0001356576-26-000028.json","markdown":"https://secwatch.observer/filing/0001356576-26-000028.md","text":"https://secwatch.observer/filing/0001356576-26-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/0001356576-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/supn-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:57:14.935854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dd5d2640a11a024e4ab778e4cb5ff3a6f251f74","claim":"SUPERNUS PHARMACEUTICALS, INC. shareholders approved To approve, on a non-binding basis, the compensation paid to our named executive officers. at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers. Votes For Votes Against Abstain Broker Non-Votes 45,552,633 1,675,355 7,714 3,073,181","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/0001356576-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"2f4e33e991c61d40cb83a803813df8d910e5abbe","claim":"SUPERNUS PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstain Broker Non-Votes 49,882,228 417,336 9,319 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/0001356576-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"72eb721a5da7a86fd04cf7d2952102191d98ba65","claim":"SUPERNUS PHARMACEUTICALS, INC. shareholders approved To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the Plan. at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the \"Plan\") to increase the number of shares available under the Plan. Votes For Votes Against Abstain Broker Non-Votes 41,925,692 5,302,088 7,922 3,073,181","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/0001356576-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"fac61f71df4a1f3999818ca204b6c24ececabd03","claim":"SUPERNUS PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2026-06-18 meeting.","evidence_excerpt":"Proposal 1: Election of Class I Directors, each to serve until the Annual Meeting of the Company in 2029. Name Votes For Votes Withheld Broker Non-Votes Frederick M. Hudson 45,058,634 2,177,068 3,073,181 Charles W. Newhall, III 41,743,154 5,492,548 3,073,181","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657626000028/0001356576-26-000028-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}